- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00005005
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis
Descripción general del estudio
Descripción detallada
The PaTH study is a 2-year, multicenter, double-blind, placebo-controlled trial to test the efficacy of combining hPTH (1-84) and alendronate for treating osteoporosis in postmenopausal women.
238 women were randomized between 55 and 85 years of age to receive either: (1) PTH for 1 year followed by alendronate for 1 year; (2) PTH and alendronate for 1 year followed by alendronate for 1 year; (3) alendronate for 2 years; or (4) PTH for 1 year followed by placebo for 1 year. The primary endpoints are changes in bone mineral density at several sites and changes in biochemical markers.
In addition, we will assess specific biochemical markers of bone turnover (e.g., osteocalcin, deoxypridinoline, N-telopeptide, bone-specific alkaline phosphatase and bone sialoprotein) to determine if they can predict the skeletal response to combination therapy. We will also determine whether PTH positively affects ultrasound measurements in the calcaneus.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maine
-
Bangor, Maine, Estados Unidos, 04401
- Maine Center for Osteoporosis
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55415
- University of Minnesota
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- University of Pittsburgh Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged between 55 and 85 years
- Postmenopausal (have not had any menses in the last 5 years)
- Have a bone mineral density scan (DXA) that can be evaluated at the spine AND at the hip with a T-score equal to or below -2.5 at the spine or the femoral neck or total hip OR T-score equal to or below -2.0 at the spine or the femoral neck or total hip and have at least one of the following risk factors for fracture: (a) age > 65 years; (b) history of postmenopausal fracture (nonvertebral or vertebral); or (c) maternal history of hip fracture
- Willing and able to self-administer daily injections
Exclusion Criteria:
- Have used estrogen (oral or patch) for more than 1 month in the last 6 months or more than 12 months in the last 2 years
- History of more than 12 months of bisphosphonate use ever, or any use (> 4 weeks) within the past 12 months
- History of rhPTH (recombinant human PTH) use
- Any major life-threatening illnesses
- Type 1 or uncontrolled type 2 diabetes mellitus (defined as hemoglobin A1C > 10.0), or currently using insulin
- Vitamin D level < 15 nanograms/ml
- History of kidney disease (creatinine > 2.0 mg/dl)
- Renal insufficiency (creatinine clearance < 40 mg/min)
- Any history of kidney stones
- Any history of hypercalciuria or currently have urine calcium/creatinine >300 mg
- History of hypercalcemia, sarcoidosis, or hyperparathyroidism
- History of active or treated tuberculosis or other granulomatous disorders
- History of breast cancer, melanoma, or hematologic malignancy that has required treatment within the last 10 years
- History of bone cancer or any other metabolic bone disease that has required treatment within the last 10 years
- History of any other nonskin cancer that has required treatment within the last 10 years
- History of symptomatic esophageal reflux, achalasia or esophageal stricture
- Currently taking > 7.5 mg systemic prednisone or equivalent per day
- Currently using > two puffs, four times/day of inhaled steroids
- Currently taking anticoagulants or anticonvulsants
- Have used Calcitonin within the past 3 months
- Have used Raloxifene in the last 6 months or for more than 12 months in the last 2 years
- Have used Tamoxifen in the last 6 months or for more than 12 months in the last 2 years
- Have used fluoride for at least a month within the past 5 years
- Currently taking > 1000 IU/day vitamin D or vitamin D analogues or metabolites
- Currently taking thyroid hormone replacement AND have a TSH < 0.1mIU/L
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 1
Participants will receive PTH for 1 year followed by alendronate for 1 year.
|
|
Experimental: 2
Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
|
|
Experimental: 3
Participants will receive alendronate for 2 years.
|
|
Comparador activo: 4
Participants will receive PTH for 1 year followed by placebo for 1 year.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Changes in bone mineral density at several sites and changes in biochemical markers
Periodo de tiempo: Year 2
|
Year 2
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Predictive value of specific biochemical markers of bone turnover
Periodo de tiempo: Year 2
|
Year 2
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Dennis Black, PhD, University of California, San Francisco
Publicaciones y enlaces útiles
Publicaciones Generales
- Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-15. doi: 10.1056/NEJMoa031975. Epub 2003 Sep 20.
- Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005 Aug 11;353(6):555-65. doi: 10.1056/NEJMoa050336.
- Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006 Apr;91(4):1370-5. doi: 10.1210/jc.2005-1712. Epub 2006 Jan 31.
- Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int. 2007 Jul;18(7):973-9. doi: 10.1007/s00198-007-0336-x. Epub 2007 Feb 28.
- Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab. 2007 Mar;92(3):942-7. doi: 10.1210/jc.2006-1788. Epub 2006 Dec 12.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- N01 AR92245
- N01AR002245-000 (Subvención/contrato del NIH de EE. UU.)
- NIAMS-045
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Osteoporosis
-
Radius Health, Inc.TerminadoOsteoporosis | Riesgo de osteoporosis | Osteoporosis Posmenopáusica | Fractura de osteoporosis | Osteoporosis relacionada con la edad | Osteoporosis localizada en la columna vertebral | Osteoporosis senil | Osteoporosis de vértebras | Osteoporosis VertebralEstados Unidos
-
AmgenTerminadoOsteoporosis posmenopáusica (OPM)Japón
-
Appalachian State UniversityNorth Carolina Agriculture & Technical State UniversityTerminadoOsteoporosis posmenopáusica | Osteoporosis, OsteopeniaEstados Unidos
-
Deltanoid PharmaceuticalsTerminadoOsteoporosis posmenopáusica, sitios múltiples
-
Radius Health, Inc.TerminadoOsteoporosis | Osteoporosis relacionada con la edad | Osteoporosis relacionada con la edad | Osteoporosis localizada en la columna vertebral | Osteoporosis senil | Osteoporosis de vértebrasEstados Unidos, Polonia, Italia
-
Organon and CoTerminadoOsteoporosis posmenopáusica
-
AmgenTerminadoOsteoporosis posmenopáusicaEstados Unidos, Canadá, Dinamarca, Alemania, Bélgica, Colombia, Chequia, Japón, México, Polonia, Suiza, Hungría, España, Australia, Rumania, Reino Unido, India, Argentina, Brasil, República Dominicana, Estonia, Letonia, Lituania, Nueva Zelanda
-
Penn State UniversityCalifornia Dried Plum BoardActivo, no reclutando
-
Massachusetts General HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)TerminadoOsteoporosis posmenopáusicaEstados Unidos
-
Sahlgrenska University Hospital, SwedenBioGaia ABTerminadoOsteoporosis posmenopáusicaSuecia